🇺🇸 FDA
Patent

US 10202348

Compositions and methods of treating retinal disease

granted A61KA61K31/41A61K31/423

Quick answer

US patent 10202348 (Compositions and methods of treating retinal disease) held by Aldeyra Therapeutics, Inc. expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aldeyra Therapeutics, Inc.
Grant date
Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/41, A61K31/423, A61K31/426, A61K31/435